Brought to you by:
Coding and complex PAD: Register today for two SVS courses
Limited spots remain open for two popular SVS courses coming in October: the Complex Peripheral Vascular Interventions (CPVI) Skills Course on Oct. 1–2 and the Coding and Reimbursement Workshop (with optional half-day evaluation and management coding workshop) on Oct. 16–17.…
Step off Friday for SVS Vascular Health Step Challenge
The month of September begins Friday and with it, the SVS Foundation’s Vascular Health Step Challenge. The initiative challenges participants to walk 60 miles—representing the 60,000 miles of blood vessels in the human body—throughout the month, which is National Peripheral…
SVS members get ready for second annual vascular health awareness event
September’s Vascular Health Step Challenge is fast-approaching, and SVS members are preparing to step up to meet it. The challenge benefits the SVS Foundation, which asks people to walk 60 miles—representing the 60,000 miles of blood vessels in the human…
Light-activated drug-coated balloon granted FDA approval for clinical study
Alucent Biomedical has announced that the Food and Drug Administration (FDA) granted an investigational device exemption (IDE) for a U.S. clinical study of AlucentNVS, a light-activated, drug-coated balloon catheter technology. AlucentNVS combines an intravascular device with a photochemical process to…
Newest JVS peer-review title appoints editor-in-chief
The Journal of Vascular Surgery (JVS) has announced the appointment of Anahita Dua, MD, as the editor-in-chief of the Journal of Vascular Surgery-Vascular Insights (JVS-VI), the newest title in the JVS stable. Dua, an SVS member, is an associate professor…
Endologix announces first patients treated with the Detour system
Endologix has shared in a press release that the first patients underwent percutaneous transmural arterial bypass (PTAB) using the Detour system since Food and Drug Administration (FDA) approval of the system was granted. PTAB with the Detour system treats complex peripheral…
SVS responds to New York Times article on overuse of vascular interventions
In an official Society response, SVS President Joseph Mills, MD, tackles recent coverage in the mainstream media of inappropriateness in vascular care. There have been several recently published articles by respected news media outlets highlighting the deeply concerning issue of…
Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
[vc_row][vc_column][vc_column_text] In a letter to healthcare providers dated July 11, 2023, the Food and Drug Administration (FDA) communicates that the risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported based on data…
Surmodics receives FDA approval for the SurVeil drug-coated balloon
Surmodics has announced the receipt of Food and Drug Administration (FDA) approval for the SurVeil drug-coated balloon (DCB). A company press release notes that the SurVeil DCB may now be marketed and sold in the U.S. to physicians for percutaneous…
Vascular Verification Program registers first four hospitals in US—including UCSF
UC San Francisco Medical Center (UCSF) is among the first four hospitals in the U.S. to be verified as part of the American College of Surgeons’ (ACS) Vascular Verification Program (Vascular-VP), a quality program recently launched in partnership with the Society for…